Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuronetics Inc (STIM)
NASDAQ:STIM
Neuronetics (STIM) Stock Price & Analysis
258 Followers
STIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.03 - $5.07
Previous Close$1.87
Volume101.97K
Average Volume (3M)137.40K
Market Cap
$56.70M
Enterprise Value$58.87M
Total Cash (Recent Filing)$59.70M
Total Debt (Recent Filing)$62.47M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Aug 06, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding29,997,563
10 Day Avg. Volume140,164
30 Day Avg. Volume137,395
Standard Deviation0.34
R-Squared0.13
Alpha-0.00910
Financial Highlights & Ratios
Price to Book (P/B)1.61
Price to Sales (P/S)0.77
Price to Cash Flow (P/CF)6.40
P/FCF Ratio5.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit1.14
Enterprise Value/Ebitda-2.57
Forecast
1Y Price Target
$6.50Price Target Upside243.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Neuronetics News
Bulls Say, Bears Say
Bulls Say
EarningsThe company reported better-than-expected EPS of $(0.27) compared to CG’s $(0.32) and consensus $(0.31) on lower operating expense spending.
Market ExpansionFDA clearance of first-line treatment of major depressive disorder (MDD) in adolescent patients will expand Neuronetics’ total addressable market by 35%, and the company is already gaining interest from providers prior to its launch.
Revenue GrowthSTIM's Treatment revenue continues to grow double digits and the company has stayed steadfast in its cost management and operating leverage initiatives with expectations for positive cash flow in 4Q24.
Bears Say
Customer Financial HealthSTIM’s customers are becoming cash-strapped due to the cybersecurity breaches on Change Healthcare.
Customer PaymentsThe disruption delayed some customer payments to STIM, resulting in a $3 mln cash shortfall to the company.
Revenue GuidanceQ2/24 revenue was guided to $18.0M-$19.0M, below CG/Street estimates of $19.5M.
---
Ownership Overview
28.96% Insiders
13.47% Mutual Funds
4.41% Other Institutional Investors
53.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $1.03 and its highest was $5.07 in the past 12 months.
What is Neuronetics Inc’s market cap?
Currently, no data Available
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Aug 06, 2024 which is in 21 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on May 07, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.04.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -$0.27.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 29,997,562 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went down -30.667%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Among the largest hedge funds holding Neuronetics Inc’s share is First Eagle Investment Management LLC. It holds Neuronetics Inc’s shares valued at 4M.
---
Neuronetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (243.92% Upside)
$6.50 (243.92% Upside)
Blogger Sentiment
Bearish
STIM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $102.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.35%
12-Months-Change
Fundamentals
Return on Equity
-72.48%
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
---
STIM Earnings Call
Q1 2024
0:00 / 0:00
---
STIM Stock 12 Month Forecast
Average Price Target
$6.50
▲(243.92% Upside)
Technical Analysis
Best Analysts Covering STIM
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-9.21%
reiterated a buy rating 4 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -9.21% per trade.
---